Neurocrine Biosciences Delivers Record Quarter, Eyes 2027

Neurocrine Biosciences ((NBIX)) has held its Q1 earnings call. Read on for the main highlights of the call.

Neurocrine Biosciences’ latest earnings call struck an upbeat tone, blending record-breaking commercial results with visible pipeline momentum. Management acknowledged a few manageable headwinds, including seasonal payer dynamics, early-stage launch risk for Cranesity, and limited deal disclosure, but stressed that strong execution, profitability, and R&D progress collectively overshadow these concerns.

Record Net Product Sales Mark a New High

Total net product sales surpassed $800 million in the quarter for the first time in Neurocrine’s history, translating into roughly 44% year-over-year growth. The company also reported that total revenue topped $800 million, underscoring broad-based strength across its marketed portfolio.

INGREZZA Delivers Solid Growth and Reaffirmed Outlook

INGREZZA posted Q1 2026 sales of $657 million, up 20% year over year, or about 11% when adjusted for one fewer order week in the prior-year quarter. Management reiterated full-year 2026 INGREZZA revenue guidance of $2.7–$2.8 billion, signaling confidence in sustained demand despite early-year payer headwinds.

Cranesity’s Launch Gains Traction Early

Cranesity generated $153 million in Q1 2026 sales and is already annualizing at more than $600 million, reflecting a fast start for a new launch. Drivers include strong persistency, steady new patient starts, broad uptake by more than 1,200 prescribers, and supportive reimbursement trends.

High Profitability and Strong Cash Generation

Neurocrine reported approximately $200 million of net income on both GAAP and non-GAAP bases for the quarter, highlighting the profitability of its expanding franchise. GAAP earnings benefited from gains tied to equity investments and the sale of the Diurnal business, bolstering the bottom line.

Pipeline Expansion and R&D Momentum Build

The company outlined an ambitious R&D agenda, planning six new Phase 1 and four new Phase 2 programs in 2026 on top of nine Phase 1 trials already underway. Management pointed to multiple anticipated Phase 3 readouts in 2027, including osavampitor in major depressive disorder, dereclidine in schizophrenia, and NBIP‑2118 in obesity.

Gene Therapy and Early-Stage Assets Advance

Neurocrine’s Friedreich’s ataxia gene therapy is slated to enter the clinic in 2026, with patient-level Phase 1b data targeted for late 2027. NBIP‑2118, the company’s CRF2-based obesity candidate, is also expected to deliver top-line data in 2027, positioning 2027 as a key catalyst year for emerging programs.

Soleno Therapeutics Acquisition Progressing

The pending acquisition of Soleno Therapeutics, which brings the iCAT/iCAD XR program, remains on track to close in the second quarter of 2026. Management emphasized Soleno’s strong clinical results and intends to integrate its team to better serve Prader‑Willi syndrome patients in the United States.

Real-World Data Strengthens INGREZZA’s Position

New real-world, head-to-head claims data showed greater treatment persistence for INGREZZA compared with deuterated tetrabenazine over six months. The findings highlighted higher long-term continuation rates and lower switching, supporting INGREZZA’s clinical and commercial differentiation in tardive dyskinesia.

Payer Coverage and Patient Economics Remain Favorable

Approximately 70% of Medicare beneficiary lives in tardive dyskinesia and Huntington’s disease now have coverage for INGREZZA, bolstering access and uptake. For Cranesity, patient out-of-pocket costs are typically very low, often under $10 per month and frequently zero, which management said is helping adherence and persistency.

Long-Term Cranesity Data Underscore Durability

Two-year open-label data for Cranesity showed more than 80% study retention, suggesting durable engagement over time. Around 70% of adults achieved glucocorticoid doses within the physiological range with normal androgen levels, with sustained clinical benefit and no new safety signals emerging.

Q1 Gross-to-Net and Seasonality Pressures Managed

Cranesity saw modest gross-to-net pressure in the quarter, largely from commercial copay resets that management characterized as anticipated and manageable. INGREZZA continued to face predictable Q1 payer seasonality from Medicare reauthorizations and commercial copay resets, but the company said operational teams handled these recurring headwinds effectively.

Early-Stage Penetration Highlights Opportunity and Risk

Despite Cranesity’s strong launch, Neurocrine estimates it has reached only about 10% of the addressable congenital adrenal hyperplasia market so far. The company noted that most prescribers have treated just one patient to date, pointing to a large runway but also underscoring adoption risk and the need for broader physician conversion.

Acquisition and Pipeline Execution Risks Persist

Because the Soleno acquisition remains under a tender offer, management provided limited transaction-level financial details, leaving some uncertainty until the deal closes. They also acknowledged that the value of the rich late-2020s pipeline depends on successful trial execution, enrollment, and regulatory outcomes, alongside rising R&D and commercial spend from Q2 onward.

Guidance and Outlook Emphasize Growth and Investment

Management reaffirmed 2026 INGREZZA revenue guidance of $2.7–$2.8 billion and projected a non-GAAP tax rate of roughly 22–24% for the year, signaling steady profitability even as investment ramps. They plan six new Phase 1 and four new Phase 2 starts in 2026, expect multiple key data readouts in 2027, and reiterated that financial details of the Soleno deal will be discussed after the scheduled Q2 closing.

Neurocrine’s call painted the picture of a company balancing robust current performance with a deepening pipeline and measured risk-taking. Record sales, rising profitability, and strong access trends underpin the bullish narrative, while early-stage launches, acquisition integration, and development timelines introduce execution risk that investors will watch closely over the next few years.